Inhibikase Therapeutics Inc
IKT
$2.49-0.40%
End of day · as of Aug 26, 2026, 5:28 PM ET
Mkt cap
$215.21M
EV/Sales
N/A
P/E ratio
N/A
Revenue (qtr ended 2026-06-30)
N/A
EPS (H1 2026)
$-0.21
Gross Margin (qtr ended 2026-06-30)
N/A
Profit Margin (qtr ended 2026-06-30)
N/A
Beta
0.97
Div yield
N/A
Sector
Healthcare
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$19.6M. IKT currently screens at market cap $215.2M.
Use this IKT research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full IKT income, balance, and cash tables.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company in the Healthcare sector.
Latest cached Inhibikase Therapeutics Inc (IKT) net income for Jun 30, 2026 was -$19.6M. Statements: https://lician.com/financials/ikt
Inhibikase Therapeutics Inc (IKT) market capitalization is $215.2M on the latest cached snapshot.
Inhibikase Therapeutics Inc (IKT) cached previous close $2.50; day range $2.43 – $2.51; volume 244,018. Session quote: https://lician.com/quote/ikt
Inhibikase Therapeutics Inc (IKT) latest cached earnings event is "IKT earnings" on Aug 13, 2026. Earnings calendar: https://lician.com/earnings
The latest cached IKT filing is 8-K · Sep 8, 2026. Filings: https://lician.com/sec/ikt